Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 5/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | CCKAR | P32238 | 2/20 | 0.35 |
| ▸ | CCKBR | P32239 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | FURIN | P09958 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.35 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28620363 | 0.77 | AKT1 (0.47) | AKT1ACE | |
| SCHEMBL28624841 | 0.74 | AKT1 (0.51) | AKT1RENACE | |
| Trifluoroacetic Acid SCHEMBL31031959 | 0.73 | CA12 (0.38) | — | |
| SCHEMBL20263646 | 0.73 | SLC6A5 (0.44) | HRH1ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL31374723 | 0.73 | GNPAT (0.48) | AKT1ACEITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL22207661 | 0.73 | GNPAT (0.48) | AKT1ACEITGB3ITGA2B | |
| SCHEMBL22267882 | 0.72 | NMT1 (0.41) | HRH1 | |
| SCHEMBL28620366 | 0.72 | AKT1 (0.52) | AKT1RENACE | |
| SCHEMBL31374730 | 0.72 | AKT1 (0.52) | AKT1RENACE | |
| SCHEMBL17860164 | 0.72 | HRH1 (0.39) | AKT1HRH1FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046813-B1 | PROTEIN-BINDING METHOTREXATE DERIVATIVES, AND MEDICAMENTS CONTAINING THE SAME | MEDAC KLINISCHE SPEZIALPRAEP (DE) | 2010-02-24 | — | — | EP | claimed |
| US-20100041615-A1 | PROTEIN-BINDING METHOTREXATE DERIVATIVES, AND MEDICAMENTS CONTAINING THE SAME | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH | 2010-02-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041615-A1 | PROTEIN-BINDING METHOTREXATE DERIVATIVES, AND MEDICAMENTS CONTAINING THE SAME | MTX1, HMGB2, HMGB3 | AKT1 4373/4885HRH1 3534/4885REN 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.